New protease inhibitors and direct-acting antivirals for hepatitis C: Interferon's long goodbye

Gut

Volumn 61, Issue 12, 2012, Pages 1647-1652

  Dusheiko, Geoffrey ^a   Wedemeyer, Heiner ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 072; ABT 333; ABT 450; ALPHA INTERFERON; ANTIVIRUS AGENT; ASUNAPREVIR; BI 291335; BMS 791325; BOCEPREVIR; DACLATASVIR; FALDAPREVIR; GS 5885; GS 9451; HEMOGLOBIN; LOMIBUVIR; MK 5172; MK 7152; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ANEMIA; ANORECTAL DISEASE; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; COMORBIDITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; DOCTOR PATIENT RELATION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENCY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSGEUSIA; EOSINOPHILIA; GENOTYPE; HAPLOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION; INNATE IMMUNITY; LIVER CIRRHOSIS; LIVER FUNCTION; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; RELAPSE; RETREATMENT; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STEVENS JOHNSON SYNDROME; SYSTEMIC DISEASE; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; VIRAL CLEARANCE; VIROTHERAPY; VIRUS GENOME; VIRUS MUTATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT FAILURE;

EID: 84868677471     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302910     Document Type: Review

References (57)

1. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405 -16.
2. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
3. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
4. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
5. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24.
6. Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011;141:881-9.
7. Gottwein JM, Scheel TK, Jensen TB, et al. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011;141:1067-79.
8. Imhof I, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 2011; 53:1090-9.
9. Trembling PM, Tanwar S, Dusheiko GM. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection. Expert Rev Anti Infect Ther 2012;10:269-79.
10. Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology Published Online First: 21 May 2012. doi:10.1053/ j.gastro.2012.05.011
11. Estrabaud E, Vidaud M, Marcellin P, et al. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol Published Online First 30 May 2012. doi:10.1016/j.jhep.2012.05.016
12. Thompson AJ. Genetic factors and hepatitis C virus infection. Gastroenterology 2012;142:1335-9.
13. Thomas D, Zoulim F. New challenges in viral hepatitis. Gut 2012;61(Suppl 1):i1-5.
14. Jacobson IM, Pawlotsky JM, Afdhal NH, et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 2012;19 (Suppl 2):1-26.
15. Camma C, Petta S, Enea M, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology Published Online First: 12 Jul 2012. doi: 10.1002/hep.25734
16. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-44.
17. Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012;35:647-62.
18. Sarrazin C, Berg T, Cornberg M, et al. [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Z Gastroenterol 2012;50:57-72.
19. Cacoub P, Bourliere M, Lubbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012;56:455- 63.
20. Welsch C, Jesudian A, Zeuzem S, et al. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012;61(Suppl 1):i36-46.
21. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-50.
22. Poordad E, Lawitz EJ, Kowdley KV, et al. 12-week interferon free regimen of ABT-450/R+ABT-333+ ribavirin achieved SVR12 in more than 90% of treatment naive HcV genotype 1 infected subjects and 47% of previous non responders (abstract). J Hepatol 2012;56(Suppl 2):S549-50.
23. Sulkowski MS, et alRoberts S, Afdhal N, et al. Ribavirin dose modi ficatrions in treatment naive and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response rates in phase 3 studies (abstract). J Hepatol 2012;56(Suppl 2):459 -60.
24. Hézode C, et al. Dorival C, Zoulim F, et al. Safety of telaprevir or boceprevir in combination with peginterferon and ribavirin in cirrhotic non responders: first results of the French early access program (ANRS CO20-CUPIC) (abstract). J Hepatol 2012;56(Suppl 2):S4.
25. Kieffer TL, Sarrazin C, Miller JS, et al . Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46 :631-9. (Pubitemid 47436107)
26. Vermehren J, Susser S, Lange CM, et al. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b. J Viral Hepat 2012;19:120-7.
27. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009;50:1709-18.
28. Welsch C, Domingues FS, Susser S, et al. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biol 2008;9:R16.
29. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011;53:1742-51.
30. Pawlotsky JM. Is hepatitis virus resistance to antiviral drugs a threat? Gastroenterology 2012;142:1369-72.
31. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-77. (Pubitemid 46677938)
32. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010;138:447-62.
33. Susser S, Vermehren J, Forestier N, et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011;52:321-7.
34. Bartels DJ, Zhou Y, Zhang EZ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008;198:800-7.
35. Kieffer TL, De MS, Bartels DJ, et al. Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One 2012;7:e34372.
36. Sherman KE, Sulkowski MS, Zoulim F, et al. Follow-up of SVR durability and viral resistance in patients with chronic hepatitis C treated with telaprevir-based regimens: interim analysis from the EXTEND study (abstract). Hepatology Program and abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 5-8 November 2011; San Francisco, California, 2012.
37. Barnard RJ, Zeuzem S, Vierling J. Analysis of resistance-associated amino acid variants (RAVS) in non-SVR patients enrolled in a retrospective long-term follow-up analysis of boceprevir phase 3 clinical studies (abstract). Hepaology 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 5-8 November 2011; San Francisco, California, 2012.
38. Sarrazin C, Reesink H, Zeuzem S. Retreatment with telaprevir/PEG-IFN/RBV after a short exposure to telaprevir in phase I studies: interim results from a phase IIIB rollover trial (C219) (abstract). Hepaology 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 5-8 November 2011; San Francisco, California, 2012.
39. Lenz O, de Bruijne J, Vijgen L, et al. Treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with PegIFNa-2a/ribavirin (abstract). J Hepatol 2012;54(Suppl 1);S482-3.
40. Tanwar S, Trembling PM, Dusheiko GM. TMC435 for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2012;21:1193 - 1209.
41. Lenz O, Verbinnen T, Lin TI, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010;54:1878-87.
42. Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010;138:913-21.
43. Kowdley KV, Lawitz E, Crespo I, et al. ATOMIC: 97% RVR for PSI-7977+PEG/RBV×12 week regimen in HCV GT1: an end to response guided therapy (abstract)? J Hepatol 2012;56(S1-20):1.
44. Zeuzem S, Berg T, Gane E. TMC435 in HCV genotype 1 patients who have failed previous pegylated inteferon ribavirin treatment: final SVR24 results of the ASPIRE trial (abstract). J Hepatol 2012;56 (S1-20):2.
45. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366 :216-24.
46. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005;79:3851-4. (Pubitemid 40327973)
47. Zeuzem S, Arora S, Bacon B. Peg interferon lambda-1A compared to Peg interferon alpha 2a in treatment naive patients with HCV genotypes 2 or 3. First SVR24 results from EMERGE phase IIb. J Hepatol 2012;56 (Suppl 2):S5-6. Ref Type: Abstract
48. Suzuki F, Ikeda K, Toyota J, et al. Dual oral therapy with the NS5a inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS- 650032) in HCV genotype 1b infected null responders or ineligible/intolerant to peg interferon/ ribavirin (abstract). J Hepatol 2012;56(Suppl 2): s7-8.
49. Sulkowski M, Gardiner D, Lawitz E, et al. Potent viral suppression with all oral combination of daclatasvir (NS5a inhibitor) and GS7977 (NS5b inhibitor) plus or minus ribavirin in treatment naive patients with chronic HCV genotype 1, 2 or 3 (abstract). J Hepatol 2012;56(Suppl 2):S560.
50. Lawitz EJ, Poordad F, Kowdley K, et al. A 12 week interferon free regimen of ABT-450/R, ABT-072, and ribavirn was well tolerated and achieved sustained virological response in 91% treatment naive HCV IL28b CC genotype 1 infected subjects (abstract). J Hepatol 2012;56 (Suppl 2):S7.
51. Zeuzem S, Soriano V, Asselah T. SVR4 and SVR12 with an interferon free regimen of BI201335 AND BI207127, +/- ribavirin in treatment naive patients with chronic genotype 1 HCV infection: interim results of SOUND-C2 (abstract). J Hepatol 2012;56(Suppl 2):S45.
52. Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003;300:1145-8. (Pubitemid 36583099)
53. Bruno S, Battezzati PM, Bellati G, et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol 2001;34:748-55. (Pubitemid 32488791)
54. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
55. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26(Supp 1): 112S-121S. (Pubitemid 27388083)
56. Aronsohn A, Jensen D. Informed deferral: a moral requirement for entry into the HCV treatment warehouse. Hepatology Published Online First: 13 Jul 2012. doi: 10.1002/hep.25957.
57. Clark PJ, Muir AJ. Overcoming barriers to care for hepatitis C. N Engl J Med 2012;366:2436-8.